Study to Test TEV-50717 in Relieving Abnormal Involuntary Movements in Cerebral Palsy

Study Title
A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
Teva Identifier
TV50717-CNS-30081 | 2019-001807-19
ClinicalTrials.gov Identifier
NCT04200352
Study Status
Terminated
Trial Condition(s)
Cerebral Palsy, Dyskinetic
Interventions
Drug: TEV-50717
EudraCT Number
2019-001807-19

Study Description

Study TV50717-CNS-30081 is a 55-week study in which patients who have successfully completed the parent study (Study TV50717-CNS-30080) may be eligible to enroll in this study.

The primary objective of this study is to evaluate the safety and tolerability of long-term therapy with TEV-50717 in children and adolescents with DCP.

The secondary objective of this study is to evaluate the efficacy of long-term therapy with TEV-50717 in reducing the severity of DCP.

Print

Participation criteria and map of study locations

EudraCT


Key Participation Requirements

Gender
Female, Male
Age group
Child, Adult
Age Range
6 Years to 18 Years
Trial Duration
February 4, 2020 - August 19, 2023
Phase
Phase 3

Additional info

Study Type

Interventional

Location - Where to Participate

You may contact 1-888-483-8279 or email USMedInfo@tevapharm.com to obtain more information about study locations.